Exeltis UK Ltd

Exeltis UK Ltd is the United Kingdom subsidiary of the global InSud Pharma group, incorporated in 2013 and specialising in women’s healthcare. Focused on improving women’s health across all stages of life, Exeltis UK markets a range of prescription-only medicines in the areas of contraception, hormone replacement therapy (HRT), menopause management, and related women’s health conditions. Its UK product portfolio includes Slynd® (drospirenone), an estrogen-free progestin-only contraceptive pill; the Elleste range of HRT products (Elleste Solo, Elleste Duet); Femoston (estradiol/dydrogesterone) for menopausal symptoms; and Atenza XL (methylphenidate) for ADHD. Medical information enquiries can be directed to uk.medinfo@exeltis.com. Adverse events should be reported to the MHRA via the Yellow Card scheme at www.mhra.gov.uk/yellowcard or to Exeltis UK at pharmacovigilance.uk@exeltis.com.